M Boffito

Summary

Affiliation: Chelsea and Westminster Hospital
Country: UK

Publications

  1. ncbi Host determinants of antiretroviral drug activity
    Marta Boffito
    St Stephen s Centre Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    Curr Opin Infect Dis 18:543-9. 2005
  2. ncbi Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation
    Marta Boffito
    St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom
    Antimicrob Agents Chemother 55:4218-23. 2011
  3. ncbi Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 9:423-9. 2004
  4. ncbi A review of the clinical pharmacology of maraviroc. Introduction
    Marta Boffito
    St Stephens AIDS Trust, Crusaid Research Institute, St Stephen's Centre, London, UK
    Br J Clin Pharmacol 65:1-4. 2008
  5. ncbi Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    AIDS 18:1291-7. 2004
  6. ncbi Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 37:1376-84. 2004
  7. ncbi Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    Br J Clin Pharmacol 59:38-42. 2005
  8. ncbi The pharmacokinetics of HIV protease inhibitor combinations
    Marta Boffito
    PK Research, Chelsea and Westminster Hospital, London, UK
    Curr Opin Infect Dis 18:1-7. 2005
  9. ncbi Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies
    M Boffito
    Pharmacokinetic Research Unit, Chelsea and Westminster Hospital, London, UK
    Int J Clin Pract 60:1098-106. 2006
  10. ncbi Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J Antimicrob Chemother 55:542-5. 2005

Detail Information

Publications71

  1. ncbi Host determinants of antiretroviral drug activity
    Marta Boffito
    St Stephen s Centre Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    Curr Opin Infect Dis 18:543-9. 2005
    ..The potential role of pharmacogenetics in the management of HIV-1 infected individuals and drug discovery will be discussed...
  2. ncbi Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation
    Marta Boffito
    St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom
    Antimicrob Agents Chemother 55:4218-23. 2011
    ....
  3. ncbi Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 9:423-9. 2004
    ..To evaluate the steady-state pharmacokinetics and safety of two once-daily saquinavir/ritonavir (SQV/RTV) regimens, 1600/100 and 2000/100 mg, in HIV-positive patients...
  4. ncbi A review of the clinical pharmacology of maraviroc. Introduction
    Marta Boffito
    St Stephens AIDS Trust, Crusaid Research Institute, St Stephen's Centre, London, UK
    Br J Clin Pharmacol 65:1-4. 2008
  5. ncbi Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    AIDS 18:1291-7. 2004
    ..To determine the pharmacokinetics of saquinavir hard-gel capsules/ritonavir/atazanavir co-administered once daily at 1600/100/300 mg in HIV-infected individuals...
  6. ncbi Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 37:1376-84. 2004
    ..This study evaluated the steady-state pharmacokinetics of saquinavir 1000 mg twice daily (bid) and fosamprenavir 700 mg bid administered with 2 different doses of ritonavir (100 and 200 mg bid) in HIV-1-infected subjects...
  7. ncbi Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    Br J Clin Pharmacol 59:38-42. 2005
    ..To investigate whether the administration of tenofovir diproxil fumarate 300 mg once daily alters the plasma pharmacokinetics of the saquinavir hard gel/ritonavir combination in HIV-1 infected individuals...
  8. ncbi The pharmacokinetics of HIV protease inhibitor combinations
    Marta Boffito
    PK Research, Chelsea and Westminster Hospital, London, UK
    Curr Opin Infect Dis 18:1-7. 2005
    ..We review the pharmacologic rationale for the double-boosted protease inhibitor combinations and the complex drug-drug interactions that occur among different protease inhibitors when co-administered...
  9. ncbi Management of advanced HIV disease: resistance, antiretroviral brain penetration and malignancies
    M Boffito
    Pharmacokinetic Research Unit, Chelsea and Westminster Hospital, London, UK
    Int J Clin Pract 60:1098-106. 2006
    ....
  10. ncbi Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J Antimicrob Chemother 55:542-5. 2005
    ..This study examined the pharmacokinetics of twice-daily saquinavir-hg (1000 mg) in the presence of ritonavir 100 mg, dosed twice-daily and once-daily on one single occasion...
  11. ncbi Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 10:375-92. 2005
    ..In addition, the panel formulated a series of position statements that are relevant to the interpretation of current data and can aid the design of future clinical trials...
  12. ncbi Pharmacokinetics and pharmacodynamics in HAART and antibiotic therapy
    Marta Boffito
    Pharmacokinetic Research Unit, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    New Microbiol 30:346-9. 2007
    ....
  13. ncbi Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 10:469-77. 2005
    ....
  14. ncbi Lack of pharmacokinetic drug interaction between tenofovir disoproxil fumarate and nelfinavir mesylate
    Marta Boffito
    PK Research, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Antimicrob Agents Chemother 49:4386-9. 2005
    ..No interaction between tenofovir and nelfinavir was observed...
  15. ncbi Lopinavir protein binding in vivo through the 12-hour dosing interval
    Marta Boffito
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    Ther Drug Monit 26:35-9. 2004
    ..05 with both methods), suggesting a concentration-dependent binding of LPV that has not been observed in vitro. However, the clinical significance of such phenomena is still unclear...
  16. ncbi Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation
    Marta Boffito
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Antivir Ther 13:901-7. 2008
    ..We investigated the pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug intake cessation...
  17. ncbi Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients
    Marta Boffito
    Chelsea and Westminster Hospital, London, United Kingdom
    HIV Clin Trials 9:418-27. 2008
    ....
  18. ncbi Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance
    Marta Boffito
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 21:1449-55. 2007
    ..Cumulative antiretroviral exposure can result in multiclass HIV drug resistance. Experimental antiretroviral agents offer limited therapeutic benefit as resistance quickly develops after their introduction as a sole new agent...
  19. ncbi Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers
    Marta Boffito
    Department of HIV GUM Medicine, St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 52:222-7. 2009
    ..To assess the pharmacokinetics of etravirine once and twice daily without and with a preceding efavirenz intake period in healthy volunteers...
  20. ncbi Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients
    Lauro J Waters
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Antivir Ther 12:825-30. 2007
    ..This study investigated the steady-state plasma pharmacokinetics of abacavir when co-administered with atazanavir/ritonavir or lopinavir/ritonavir in HIV-infected individuals...
  21. ncbi British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)
    B Gazzard
    Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    HIV Med 7:487-503. 2006
  22. ncbi Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects
    K Singh
    St Stephen s Centre, Chelsea and Westminster NHS Foundation Trust, London, UK
    Clin Pharmacol Ther 83:867-72. 2008
    ..No grade 3/4 toxicity or lab abnormalities were observed. In the presence of omeprazole, saquinavir plasma exposure is significantly increased in HIV-infected subjects whether administered simultaneously or 2 h apart...
  23. ncbi A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects
    Anton L Pozniak
    St Stephens AIDS Trust, Chelsea and Westminster Hospital, London, UK
    Br J Clin Pharmacol 65:54-9. 2008
    ....
  24. ncbi Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals
    Laura Dickinson
    NIHR National Biomedical Research Centre, Royal Liverpool and Broadgreen University Hospital Trust, Liverpool, UK
    J Antimicrob Chemother 62:1344-55. 2008
    ....
  25. ncbi Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals
    Laura Dickinson
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    Ther Drug Monit 29:361-7. 2007
    ..It may also aid the choice of sampling times for population analysis...
  26. ncbi Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial
    Desmond Maitland
    Chelsea and Westminster Hospital, London, UK
    AIDS 19:1183-8. 2005
    ....
  27. ncbi Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
    Jennifer Ford
    Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, and PK Research Ltd, St Stephen's Centre, Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 58:1009-16. 2006
    ..Co-administration of atazanavir caused an increase in both the plasma and cellular exposure (AUC0-24) and C24 of saquinavir but not ritonavir...
  28. ncbi Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients
    Jennifer Ford
    Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Pl, Block H, First Floor, Liverpool L69 3GF, United Kingdom
    Antimicrob Agents Chemother 48:2388-93. 2004
    ..The intracellular t(1/2)s of saquinavir and ritonavir were longer than the plasma t(1/2)s, indicating that intracellular drug may be available at a time when concentrations in plasma are below the minimum effective concentration...
  29. ncbi Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression
    S Collot-Teixeira
    1Cardiovascular Division, King s College London, London, UK
    Clin Pharmacol Ther 85:375-8. 2009
    ..The ritonavir concentration in the plasma correlated with changes in triglycerides, HDL, and adipophilin (r = 0.34, P = 0.030; r = 0.33, P = 0.040; and r = 0.4, P = 0.01, respectively)...
  30. ncbi Metabolic-inflammatory changes, and accelerated atherosclerosis in HIV patients: rationale for preventative measures
    F De Lorenzo
    Beta Cell Diabetes Centre, Chelsea and Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, UK
    Curr Med Chem 15:2991-9. 2008
    ....
  31. ncbi Unexpected drug interactions and adverse events with antiretroviral drugs
    Graeme Moyle
    Chelsea and Westminster Hospital, London SW10 9NH, UK
    Lancet 364:8-10. 2004
  32. ncbi Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects
    Graeme Moyle
    Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom
    Antimicrob Agents Chemother 54:3170-8. 2010
    ..RDEA806 is a potent and promising novel NNRTI...
  33. ncbi Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1
    Graeme Moyle
    Chelsea Westminster Hospital, London, United Kingdom
    Clin Infect Dis 48:798-805. 2009
    ..The X4 Antagonist Concept Trial investigates the safety and antiviral activity of AMD11070, a potent inhibitor of X4-tropic human immunodeficiency virus (HIV) in vitro in HIV-infected patients harboring X4-tropic virus...
  34. ncbi Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies
    Marta Boffito
    PK Research, St. Stephen's Centre-Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, United Kingdom
    J Clin Pharmacol 46:130-9. 2006
    ....
  35. ncbi Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses
    Marta Boffito
    Chelsea and Westminster Hospital, London, United Kingdom
    AIDS Res Hum Retroviruses 22:749-56. 2006
    ..Atazanavir-related hyperbilirubinemia was dose dependent. However, higher saquinavir and atazanavir exposure may be required to suppress HIV-resistant strain replication...
  36. ncbi Pharmacokinetic analysis to assess forgiveness of boosted saquinavir regimens for missed or late dosing
    Laura Dickinson
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    J Antimicrob Chemother 62:161-7. 2008
    ..To give an estimation of 'forgiveness', we determined the length of time plasma drug concentrations were below target in HIV-infected patients receiving saquinavir/ritonavir regimens...
  37. ncbi Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers
    Alan Winston
    Chelsea and Westminster Hospital, London, UK
    AIDS 20:1401-6. 2006
    ..We evaluated the effect of omeprazole, a proton-pump-inhibitor, on the pharmacokinetics of the recently developed saquinavir-500 mg formulation co-administered with ritonavir...
  38. ncbi Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects
    Graeme Moyle
    St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    Antimicrob Agents Chemother 53:1532-8. 2009
    ..Women had higher intracellular CBV-TP exposure than did men...
  39. ncbi Protein binding in antiretroviral therapies
    Marta Boffito
    St. Stephens Centre, Chelsea and Westminster Hospital, London SW10 9NH, United Kingdom
    AIDS Res Hum Retroviruses 19:825-35. 2003
    ....
  40. ncbi Can we boost enough without ritonavir?
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 14:229-30, 233-5. 2004
  41. ncbi Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment
    Marta Boffito
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    AIDS Res Hum Retroviruses 18:341-2. 2002
  42. ncbi Prevention of atherosclerosis in patients living with HIV
    Ferruccio De Lorenzo
    General Medicine and Prevention of Vascular Disorders, Beta Cell Diabetes Centre and St Stephen s AIDS Trust, Chelsea and Westminster Hospital NHS Foundation Trust, London, UK
    Vasc Health Risk Manag 5:287-300. 2009
    ..For the first time, this study will investigate anti-inflammatory and anti-atherogenic effects of a pharmacological lipid-lowering agent in HIV-IP that may lead to the reduction of CVD...
  43. ncbi The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma
    Mark Bower
    Department of Oncology, Chelsea and Westminster Hospital, London, UK
    AIDS 23:1701-6. 2009
    ..A prospective cohort study was performed to evaluate the clinical outcomes of patients with histologically confirmed AIDS-related Kaposi's sarcoma diagnosed since the introduction of HAART...
  44. ncbi Drug-drug interactions involving new antiretroviral drugs and drug classes
    Jesse Soodalter
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Curr Opin Infect Dis 22:18-27. 2009
    ..The aim of this article is to review the available data on new antiretroviral agents and the drug-drug interactions studied so far...
  45. ncbi Nucleoside/nucleotide reverse transcriptase inhibitor drug interactions
    Yohan P Samarasinghe
    PK Research-St. Stephen's Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J HIV Ther 9:79-86. 2004
    ..This article aims to identify clinically relevant, beneficial and detrimental interactions of this class of antiretroviral agent...
  46. ncbi The relationship between nevirapine plasma concentrations and abnormal liver function tests
    Lisa M Almond
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK
    AIDS Res Hum Retroviruses 20:716-22. 2004
    ..228; p = 0.04). Overall we found no strong association between NVP concentrations and hepatotoxicity. Although in this study NVP was well tolerated in HCV/HBV coinfected patients, higher plasma concentrations were observed...
  47. ncbi The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects
    Marta Boffito
    Department of Pharmacology and Therapeutics, University of Liverpool, UK
    Br J Clin Pharmacol 54:262-8. 2002
    ....
  48. ncbi Simultaneous determination of rifampicin and efavirenz in plasma
    Marta Boffito
    Department of Pharmacology and Therapeutics, Univeristy of Liverpool, United Kingdom
    Ther Drug Monit 24:670-4. 2002
    ..This HPLC method is highly sensitive and precise, suitable for pharmacokinetic studies or routine clinical monitoring of rifampicin and efavirenz simultaneously in HIV patients with tuberculosis...
  49. ncbi Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitors
    Akil Jackson
    Chelsea and Westminster Hospital, London, United Kingdom
    AIDS Rev 6:208-17. 2004
    ....
  50. ncbi The management of HIV-1 protease inhibitor pharmacokinetic interactions
    Alan Winston
    St Stephen's Centre, Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 56:1-5. 2005
    ..This review will focus on the current use of PIs, highlighting some important management issues encountered with common pharmacokinetic interactions seen in clinical practice...
  51. ncbi Pharmacokinetic considerations for combining 2 protease inhibitors
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 14:110-2, 115-6. 2004
  52. ncbi Investigation of low-dose ritonavir on human peripheral blood mononuclear cells using gene expression whole genome microarrays
    Saliha Yilmaz
    Cardiovascular Division, King s College London, 150 Stamford Street, London, UK
    Genomics 96:57-65. 2010
    ..Lower expression levels of these 4 candidate genes, known to play a critical role in inflammation, lipid metabolism and atherosclerosis, may explain ritonavir adverse effects in patients...
  53. ncbi Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs
    Marta Sousa
    St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J Antimicrob Chemother 62:872-8. 2008
    ..e. quinine). The aim of this paper is to review known and potential drug-drug interactions between rifampicin, rifabutin and antimalarial drugs...
  54. ncbi Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting
    Marta Boffito
    Ther Drug Monit 24:574-6. 2002
  55. ncbi Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics
    Marta Boffito
    Department of Infectious Diseases, University of Torino, Turin, Italy
    AIDS 16:2081-3. 2002
    ..On multivariate analysis, a lopinavir concentration of 5.7 microg/ml or greater was an independent predictor of viral suppression over a 9-month follow-up period...
  56. ncbi Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with kaposi's sarcoma
    Marta Boffito
    Antimicrob Agents Chemother 46:3684-5. 2002
  57. ncbi Pharmacokinetics of saquinavir co-administered with cimetidine
    Marta Boffito
    Infectious Diseases Unit, University of Torino, Torino, Italy
    J Antimicrob Chemother 50:1081-4. 2002
    ..Further pharmacokinetic studies in HIV-infected subjects are warranted to confirm the boosting effect of cimetidine and to investigate any impact that the increase in saquinavir C(max) may have on intracellular accumulation of the drug...
  58. ncbi Lopinavir/ritonavir absorption in a gastrectomized patient
    Marta Boffito
    AIDS 17:136-7. 2003
  59. ncbi Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring
    Marta Boffito
    AIDS 17:1107-8. 2003
  60. ncbi Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients
    Reshma Saskia Autar
    The HIV Netherlands Australia Thailand Research Collaboration, Thai Red Cross AIDS Research Centre, Bangkok, 104 Rajdumri Road, 10330 Pathumwan, Bangkok, Thailand
    J Antimicrob Chemother 56:908-13. 2005
    ..Differential exposure to saquinavir/ritonavir may lead to therapy failure. The objective was to identify factors that influence variability of saquinavir/ritonavir plasma concentrations...
  61. ncbi The clinical pharmacology of antiretrovirals in development
    Alan Winston
    Imperial College, Clinical Trials Unit, Ground Flood, Winston Churchill Wing, St Mary s Hospital, Praed Street, London W2 1NY, UK
    Expert Opin Drug Metab Toxicol 2:447-58. 2006
    ..This review reports the known data on the pharmacokinetics of experimental antiretrovirals, and describe the main drug-drug interactions studied so far...
  62. ncbi The clinical implications of antiretroviral pharmacogenomics
    Julie Fox
    St. Mary's Hospital, Clinical Trials Centre, Winston Churchill Wing, Division of Medicine, Imperial College London, Praed Street, London W2 1NY, UK
    Pharmacogenomics 7:587-96. 2006
    ..This review summarizes the key findings in the growing knowledge between human genetics and response to antiretroviral drugs and how these findings may be effectively applied in a clinical context...
  63. ncbi Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response
    Alan Winston
    J Acquir Immune Defic Syndr 41:675-6. 2006
  64. ncbi Stopping antiretroviral therapy
    Stephen Taylor
    Directorate of Sexual Medicine and HIV, Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Bordesly Green East, Birmingham, UK
    AIDS 21:1673-82. 2007
  65. ncbi Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine
    Stefano Bonora
    AIDS 18:577-8. 2004
  66. ncbi Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors
    Marta Boffito
    Clin Infect Dis 34:558-9. 2002
  67. ncbi Treating advanced HIV infection
    Marta Boffito
    J Acquir Immune Defic Syndr 34:344-5. 2003
  68. ncbi Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting
    Marta Boffito
    AIDS Res Hum Retroviruses 19:941-2. 2003
  69. ncbi Simvastatin co-prescribed with protease inhibitors despite dangerous drug interactions
    Katherine M Coyne
    Sex Transm Infect 83:498. 2007
  70. ncbi Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens
    Marta Boffito
    Drug Metab Dispos 30:859-60. 2002
  71. ncbi Antiretroviral therapy to reduce the sexual transmission of HIV
    Stephen Taylor
    Department of Sexual Medicine, Brimingham Heartlands Hospital, Birmingham B9 5SS, UK
    J HIV Ther 8:55-66. 2003
    ..In the worst-case scenario, antiretroviral therapy may simply increase the transmission of drug-resistant virus...